A program to advance new drug development for neglected diseases such as mycetoma, tuberculosis and malaria through partnerships with GHIT Fund, DNDi, MMV, academic institutions and others. It includes the clinical development and regulatory filing preparations for multiple candidates, including E1224 and E1018.